Database : MEDLINE
Search on : Panniculitis [Words]
References found : 3646 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 365 go to page                         

  1 / 3646 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29524269
[Au] Autor:Santos Briz A; Calle A; Linos K; Semans B; Carlson A; Sangüeza OP; Metze D; Cerroni L; Díaz-Recuero JL; Alegría-Landa V; Mascaró JM; Moreno C; Rodríguez-Peralto JL; Requena L
[Ad] Address:Department of Pathology, Hospital Clínico Universitario, Salamanca, Spain.
[Ti] Title:Dermatomyositis panniculitis: A clinico-pathologic and immunohistochemical study of 18 cases.
[So] Source:J Eur Acad Dermatol Venereol;, 2018 Mar 10.
[Is] ISSN:1468-3083
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Panniculitis occurring in dermatomyositis is uncommon, with only a few cases described in the literature, most of them as case reports. OBJECTIVE: This report describes the clinico-pathological and immunohistochemical findings in a series of 18 patients with panniculitis associated to dermatomyositis. METHODS: In each patient we collected the clinical data of the cutaneous lesions as well as the characteristic clinical and laboratory findings. A series of histopathologic findings was recorded in the biopsy of each patient. A panel of antibodies was used in some cases to investigate the immunophenotype of the infiltrate. Data of treatment and follow-up were also collected. RESULTS: Of the 18 patients, 13 were female and 5 were male, ranging in age from 13 to 74 years (median, 46,4 years). In addition to panniculitis, all patients presented pathognomonic cutaneous findings of DM and reported proximal muscle weakness prior to the diagnosis of panniculitis. Muscle biopsy was performed in 17 patients and MRI in one, all with the diagnosis of inflammatory myopathy. None of the patients presented any associated neoplasia. Panniculitis lesions were located in the upper or lower limbs. Histopathology showed a mostly lobular panniculitis with lymphocytes as the main component of the infiltrate. Most cases showed also numerous plasma cells and lymphocytes surrounding necrotic adipocytes (rimming) were frequently seen. Lymphocytic vasculitis and abundant mucin interstitially deposited between collagen bundles of the dermis were also frequent findings. Late stage lesions showed hyaline necrosis of the fat lobule and calcification. Immunohistochemistry demonstrated that most lymphocytes of the infiltrate were T-helper lymphocytes, with some B-lymphocytes in the lymphoid aggregates and small clusters of CD-123 positive plasmacytoid dendritic cells in the involved fat lobule. CONCLUSION: Panniculitis in dermatomyositis is rare. Histopathologic findings of panniculitis dermatomysositis are identical to those of lupus panniculitis. Therefore, the final diagnosis requires clinic-pathologic correlation. This article is protected by copyright. All rights reserved.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher
[do] DOI:10.1111/jdv.14932

  2 / 3646 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29516893
[Au] Autor:Boyd AS
[Ad] Address:Department of Dermatology; Department of Pathology, Division of Dermatopathology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
[Ti] Title:Cutaneous infection with .
[So] Source:Int J Mycobacteriol;7(1):92-94, 2018 Jan-Mar.
[Is] ISSN:2212-554X
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:This report describes the presence of cutaneous nodules and ulceration of the right leg of 1-year duration in an elderly woman. Prior biopsies had demonstrated dermal and subcutaneous granulomatous inflammation. Special stains for microorganisms and cultures were repeatedly negative. Polymerase chain reaction evaluation of the tissue block demonstrated the presence of Mycobacterium obuense.
[Pt] Publication type:CASE REPORTS
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Data-Review
[do] DOI:10.4103/ijmy.ijmy_7_18

  3 / 3646 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29504978
[Au] Autor:Zhang R; Dang X; Shuai L; He Q; He X; Yi Z
[Ad] Address:Laboratory of Pediatric Nephrology, Instiute of Pediatrics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
[Ti] Title:Lupus erythematosus panniculitis in a 10-year-old female child with severe systemic lupus erythematosus: A case report.
[So] Source:Medicine (Baltimore);97(3):e9571, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Lupus erythematosus panniculitis (LEP) is a rare subset of lupus erythematosus. The incidence of LEP in systemic lupus erythematosus (SLE) ranges from 2% to 5%. In the previous literature, most LEP patients were women aged from 20 to 60 years, while pediatric cases were rare, all of whom appeared on their own without SLE.A rare LEP in a 10-year-old female child with severe SLE is presented. PATIENT CONCERNS: A 10-year-old girl was admitted to our hospital for marasmus and fatigue without other typical manifestations of SLE well before the appearance of skin lesions. The only proof to support the SLE is that we observed a weakly positive antinuclear antibody (ANA) in serum at the onset. DIAGNOSES: A 10-year-old girl diagnosed to the Division of Nephrology, Department of Pediatrics, the Second Xiangya Hospital, Central South University, for LEP with severe SLE. INTERVENTIONS: The patient was administered with high-dose corticosteroids and cyclophosphamide. OUTCOME: The patient died of severe lung involvement despite the use of high-dose corticosteroids and cyclophosphamide. LESSONS: This report highlights an unusual manifestation of LEP associated with SLE in a child. It also suggests that pediatricians should be aware of occult onset of SLE, such as unclear marasmus and fatigue found in this case. Repeat tests of antinuclear antibody and anti-double strand DNA antibody (anti-dsDNA) as well as renal biopsy in a timely manner will be effective to achieve early recognition and immediate treatment for saving lives.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Process
[do] DOI:10.1097/MD.0000000000009571

  4 / 3646 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29293267
[Au] Autor:Dittmer MR; Willis MS; Selby JC; Liu V
[Ad] Address:Carver College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa.
[Ti] Title:Septolobular panniculitis in disseminated Lyme borreliosis.
[So] Source:J Cutan Pathol;45(4):274-277, 2018 Apr.
[Is] ISSN:1600-0560
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Lyme disease classically evolves through clinical manifestations according to the stage of illness. Because many of the systemic symptoms are non-specific, and because serology may yield false negative results, cutaneous findings merit even greater importance to diagnosis. The prototypical skin lesion, erythema migrans (EM), occurs early and is the only independent diagnostic clinical feature according to the guidelines of the Infectious Diseases Society of America. EM itself has protean guises, being, at times, vesicular, indurated, necrotic, purpuric, solid, or targetoid, but it is not the sole Borrelia-associated skin lesion. Acrodermatitis chronica atrophicans and borrelial lymphocytoma cutis are other well-known skin manifestations. A rare cutaneous manifestation that is increasingly reported in Lyme patients is panniculitis, which develops after dissemination of the spirochete. We present such a case in a patient who was initially treated for cellulitis as well as neck and radicular leg pain, thereby expanding the cutaneous spectrum of Lyme disease.
[Pt] Publication type:CASE REPORTS
[Em] Entry month:1801
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[St] Status:In-Process
[do] DOI:10.1111/cup.13100

  5 / 3646 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29490158
[Au] Autor:Williams DS
[Ti] Title:Mesenteric Panniculitis.
[So] Source:J Insur Med;47(2):130-132, 2017.
[Is] ISSN:0743-6661
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Mesenteric panniculitis is a rare, benign, and chronic fibrosing inflammatory disease that affects the adipose tissue of the small intestine and colon.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180228
[Lr] Last revision date:180228
[St] Status:In-Data-Review
[do] DOI:10.17849/insm-47-02-130-132.1

  6 / 3646 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29470303
[Au] Autor:Llamas Velasco M; Pérez-Gónzalez YC; Kempf W; Paredes BE; Cerroni L; Fernández Figueras MT
[Ad] Address:Dermatology Faculty, Department of Dermatology, Hospital Universitario de La Princesa, Madrid, Spain.
[Ti] Title:Clues in Histopathological Diagnosis of Panniculitis.
[So] Source:Am J Dermatopathol;40(3):155-167, 2018 Mar.
[Is] ISSN:1533-0311
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Panniculitides comprise a group of heterogeneous inflammatory diseases. Nevertheless, histopathological study along with clinicopathological correlation usually led to a specific diagnosis. In most textbooks, the first step in the diagnosis is to classify them as mostly septal or lobular depending on where the inflammatory infiltrate is located. The second step is deciding if vasculitis is present or not. Finally, the third step is further characterizing the inflammatory infiltrate. However, in addition to the algorithmic approach to panniculitis diagnosis, some subtle changes may help to the diagnosis. OBJECTIVE: To review some clues in panniculitis dermatopathological diagnosis such as presence of granulation tissue, sclerotic connective tissue septa, small granulomas arranged around a central clear space, so-called ghost adipocytes, needle-shaped crystals, small lobules with a proliferation of capillaries, Splendore-Hoeppli phenomenon, refractile microspheres, neutrophilic infiltrates, granulomas and fibroplasia or presence of adipose tissue in dermis. METHODS: We have compiled 12 clues based in our personal experience in this field. LIMITATIONS: Specificity and sensibility of every clue may vary and these clues are a guide to correct diagnoses that should rely in clinicopathological correlation. CONCLUSION: Knowledge of these 12 clues will help to increase the diagnostic accuracy in panniculitis diagnosis.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[St] Status:In-Process
[do] DOI:10.1097/DAD.0000000000000985

  7 / 3646 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29288667
[Au] Autor:Oishi K; Ohyama S; Higo-Yamamoto S
[Ad] Address:Biological Clock Research Group, Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki, Japan; Department of Applied Biological Science, Graduate School of Science and Technology, Tokyo University of Science, Noda, Chiba, Japan; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Chiba, Japan. Electronic address: k-ooishi@aist.go.jp.
[Ti] Title:Chronic sleep disorder induced by psychophysiological stress induces glucose intolerance without adipose inflammation in mice.
[So] Source:Biochem Biophys Res Commun;495(4):2616-2621, 2018 01 22.
[Is] ISSN:1090-2104
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Sleep disturbances are associated with various metabolic diseases such as hypertension and diabetes. We had previously established a mouse model of a psychophysiological stress-induced chronic sleep disorder (CSD) characterized by disrupted circadian rhythms of wheel-running activity, core body temperature, and sleep-wake cycles. To evaluate the underlying mechanisms of metabolic disorders induced by CSD, we created mice with CSD for six weeks and fed them with a high-fat diet. Glucose intolerance with hyperglycemia resulted, although plasma insulin levels and body weight increases were identical between control and CSD mice. Gluconeogenesis and glycolysis were enhanced and suppressed, respectively, in the livers of CSD mice, because the mRNA expression of Pck1 was significantly increased, whereas that of Gck and Pklr were significantly decreased in the CSD mice. Adipose inflammation induced by the high-fat diet seemed suppressed by the CSD, because the mRNA expression levels of Adgre1, Ccl2, and Tnf were significantly downregulated in the adipose tissues of CSD mice. These findings suggest that CSD impair glucose tolerance by inducing gluconeogenesis and suppressing glycolysis. Hyperphasia with hypoleptinemia, hypercorticosteronemia, and increased plasma free fatty acids might be involved in the impaired glucose metabolism under a CSD. Further studies are needed to elucidate the endocrine and molecular mechanisms underlying the associations between sleep disorders and impaired glucose homeostasis that consequently causes diabetes.
[Mh] MeSH terms primary: Glucose Intolerance/etiology
Glucose Intolerance/physiopathology
Sleep Wake Disorders/etiology
Sleep Wake Disorders/physiopathology
Stress, Psychological/complications
Stress, Psychological/physiopathology
[Mh] MeSH terms secundary: Animals
Chronic Disease
Cytokines/metabolism
Male
Mice
Panniculitis/etiology
Panniculitis/physiopathology
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Cytokines)
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[Js] Journal subset:IM
[Da] Date of entry for processing:171231
[St] Status:MEDLINE

  8 / 3646 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29469793
[Au] Autor:Benavente-Villegas F; Ferrando-Roca F; Dolz-Gaitón R; Royo-Peiró M
[Ad] Address:Department of Dermatology, Dermatologist, Hospital Universitario Doctor Peset, Valencia, Spain. elipecbv@gmail.com.
[Ti] Title:Lesiones subcutáneas dolorosas en paciente con melanoma metastásico: un caso de paniculitis linfocítica asociado a vemurafenib.
[So] Source:Dermatol Online J;23(10), 2017 Oct 15.
[Is] ISSN:1087-2108
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Vemurafenib ha probado ser una herramienta útil en el tratamiento de melanoma metastásico con mutación BRAF-V600E. Los efectos adversos incluyen artralgias, fatiga y toxicidad cutánea, siendo infrecuente la paniculitis. Presentamos el caso de una paciente de 43 años con melanoma metastásico que desarrolla lesiones subcutáneas dolorosas en miembros inferiores y superiores, asociadas a clínica sistémica después de 2 semanas de inicio de tratamiento con Vemurafenib + Cobimetinib. La histología demostró paniculitis linfocitaria septal y lobulillar. La paciente tuvo mala tolerancia al tratamiento anti diana a dosis plenas, requiriendo su ajuste, generando una corticodependencia para controlar sintomatología, y que finalmente obligó a la descontinuación de la terapia dirigida contra melanoma.  A la fecha, se han descrito 29 casos en la literatura de paniculitis asociada a vemurafenib, siendo la mayoría paniculitis neutrofílicas con adecuado control de sintomatología asociando antiinflamatorios no esteroidales y/o corticoides orales sin requerir en su mayoría modificación de la terapia contra melanoma; sin embargo hay que tener presente que pueden haber casos con mala evolución que obligan a la reducción de dosis de vemurafenib y descontinuar el tratamiento, como ha ocurrido en nuestro reporte.Vemurafenib has proven to be a useful tool in the treatment of metastatic melanoma with BRAF-V600E mutation. Adverse effects include arthralgia, fatigue, and skin toxicity; panniculitis is a rare complication. We present the case of a 43-year-old patient with metastatic melanoma who developed painful subcutaneous nodules of the lower and upper limbs and associated systemic clinical symptoms after 2 weeks of treatment with vemurafenib plus cobimetinib. Histology showed a septal and lobular lymphocytic panniculitis.The patient had poor tolerance of the full-dose treatment, requiring its adjustment. Systemic corticosteroids were required to control symptomatology, which finally forced the discontinuation of the medication.To date, 29 cases have been described in the literature of panniculitis associated with vemurafenib. Most of these have been neutrophilic panniculitis, but adequate control of symptoms is usually achieved with nonsteroidal anti-inflammatory drugs and/or oral corticosteroids without requiring modification of melanoma therapy. However, it must be borne in mind that there may be cases that force the reduction and discontinuation ofvemurafenib treatment. We believe that this histological variant of lymphocytic panniculitis and its poor response to decrease in vemurafenib makes this case unusual and instructive.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[St] Status:In-Process

  9 / 3646 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29395885
[Au] Autor:Escudier A; Mauvais FX; Bastard P; Boussard C; Jaoui A; Koskas V; Lecoq E; Michel A; Orcel MC; Truelle PE; Wohrer D; Piram M
[Ad] Address:Université de médecine Paris-Descartes, 12, rue de l'École-de-Médecine, 75006 Paris, France. Electronic address: agathe@escudier.eu.
[Ti] Title:Peau et fièvres récurrentes auto-inflammatoires. [Dermatological features of auto-inflammatory recurrent fevers].
[So] Source:Arch Pediatr;25(2):150-162, 2018 Feb.
[Is] ISSN:1769-664X
[Cp] Country of publication:France
[La] Language:fre
[Ab] Abstract:Auto-inflammatory diseases are characterized by unexplained and recurrent attacks of systemic inflammation often involving the skin, joints, or serosal membranes. They are due to a dysfunction or dysregulation of the innate immunity, which is the first line of defense against pathogens. Early recognition of these diseases by the clinician, especially by pediatricians encountering such pathologies in pediatric patients, is primordial to avoid complications. Skin manifestations, common in most auto-inflammatory diseases, are helpful for prompt diagnosis. After a brief physiopathological review, we will describe auto-inflammatory recurrent fevers by their main dermatological presentations: urticarial lesions, neutrophilic dermatoses, panniculitis, other maculopapular eruptions, dyskeratosis, skin vasculitis, and oral aphthous. We finally suggest a decision tree to help clinicians better target genetic exams in patients with recurrent fevers and dermatological manifestations.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180221
[Lr] Last revision date:180221
[St] Status:In-Process

  10 / 3646 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29433571
[Au] Autor:Tetzlaff MT; Nelson KC; Diab A; Staerkel GA; Nagarajan P; Torres-Cabala CA; Chasen BA; Wargo JA; Prieto VG; Amaria RN; Curry JL
[Ad] Address:Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
[Ti] Title:Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.
[So] Source:J Immunother Cancer;6(1):14, 2018 Feb 12.
[Is] ISSN:2051-1426
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Immune checkpoint therapy has dramatically changed the landscape of cancer therapy, providing an efficacious and durable therapeutic option for patients with advanced-stage disease. However, dermatologic toxicities are a well-recognized side effect in patients receiving this therapy. A spectrum of immune related adverse events (irAEs) involving the skin can occur and include immunobullous disorders, lichenoid dermatitis, and vitiligo. Granulomatous/sarcoid-like lesions are now being recognized with the current class of checkpoint inhibitors (CPIs) that involve the dermis, the subcutaneous tissue (panniculitis), and lymph nodes. CASE PRESENTATION: We report 3 patients who developed granulomatous/sarcoid-like lesions while being treated with immune checkpoint therapy for advanced-stage melanoma, and we provide a comprehensive review of the literature in which similar cases are described. To date, 26 patients (including the 3 from this report) have been described with a median age of 57 years who developed granulomatous/sarcoid-like lesions associated with CPIs (median onset 6 months), of which 77% of patients had melanoma as primary tumor. To manage this adverse side effect, therapy was withheld in 38% of patients and 44% of the patients were treated with systemic steroids and 8% patients with localized therapy (one patient with intralesional triamcinolone). 96% of patients demonstrated either resolution or improvement of granulomatous/sarcoid-like lesions associated with CPIs irrespective of medical intervention. Therapeutic response, stable disease, or remission of primary malignancy was observed in 71% of reported patients who developed granulomatous/sarcoid-like lesions associated with CPIs over a median follow-up of 11.5 months since initiation of treatment. CONCLUSIONS: The development of granulomatous/sarcoid-like lesions associated with CPIs is a recognized manifestation with the current class of immune checkpoint therapy that may clinically and radiographically mimic disease recurrence. Awareness of this type of toxicity is important for appropriate management and possible measurement of therapeutic response in a subset of patients who manifest this type of immune-mediated reaction.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180218
[Lr] Last revision date:180218
[St] Status:In-Data-Review
[do] DOI:10.1186/s40425-018-0323-0


page 1 of 365 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information